Skip to main content
Fig. 6 | BMC Medicine

Fig. 6

From: DNA methylation subtypes guiding prognostic assessment and linking to responses the DNA methyltransferase inhibitor SGI-110 in urothelial carcinoma

Fig. 6

Guadecitabine (SGI-110), a DNA methyltransferase inhibitor, showed therapeutic effects in T24 and UMUC-3 cells. A, B Cell migration capacity with or without SGI-110 treatment was evaluated through wound healing assays. Values are the mean ± SD of eight independent experiments. C, D Cell invasion capacity with or without SGI-110 treatment was evaluated through Transwell assays. The bar chart on the right represents the number of cells passing through the compartment. Data are presented as the means ± SEM. n = 3. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us